24/7 Market News Snapshot 09 July, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (SLXN) continues to capture investor interest, as evidenced by its 13.09% increase in pre-market trading, elevating its share price to $0.916, up from $0.810 in the previous session. This surge, accompanied by a significant trading volume of 5.00 million shares, suggests a burgeoning bullish sentiment surrounding the company. Technical indicators point to a potential breakthrough of key resistance levels, with traders advised to monitor support around $0.850 and resistance at approximately $0.950 for insights on future price movements.

In a notable development, Silexion has announced promising preclinical results for its innovative RNA interference (RNAi) therapy, SIL204, targeted at KRAS-driven lung cancers. This therapy is particularly critical, as KRAS mutations are present in approximately 30% of lung cancer cases and are known to be among the hardest oncogenic challenges in current oncology treatments. SIL204 has demonstrated impressive dose-dependent inhibition of lung cancer cells featuring KRAS G12D mutations, indicating its potential as a transformative treatment for this specific cancer subtype.

The company is also expanding its research by conducting another study on a previously untested KRAS mutation, with anticipated results that could further validate SIL204 as a pan-KRAS therapeutic option. Silexion remains committed to its dual-route administration strategy—utilizing both intratumoral and systemic delivery to improve therapeutic efficacy. A Phase 2/3 clinical trial is expected to commence in the second quarter of 2026, focusing on evaluating SIL204’s effectiveness in treating KRAS-driven solid tumors.

Chairman and CEO Ilan Hadar expressed optimism regarding the recent findings, highlighting the advancements made in enhancing drug delivery into tumor cells. These advancements not only reaffirm Silexion’s potential in addressing significant oncology challenges but also reinforce its dedication to pioneering RNA-based cancer therapies for patients with limited options.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.